Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early Breast Cancer.
Phase of Trial: Phase 0
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- 15 Jul 2019 Protocol has been amednded with the addition of 2 more treatment arms and planned number of patients also increasing from 34 to 54
- 15 Jul 2019 Planned number of patients changed from 34 to 54.
- 15 Jul 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.